PDCD1 and melanoma: To further test whether the ssMutPA approach could identify key pathways and cancer subtypes associated with response to ICIs, we applied ssMutPA to the Liu et al. cohort, comprising 105 patients with melanoma treated with the PD-1 inhibitor [33].